Trial Profile
A randomised, placebo-controlled, four way crossover study to evaluate the effect of double-blind 4000 mcg of orally inhaled GW685698X and of 6.25 mg cellobiose octa-acetate on electrocardiographic parameters, with single-blind 400 mg of oral moxifloxacin as a positive control, in 40 healthy male and female subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 27 Aug 2023
Price :
$35
*
At a glance
- Drugs Fluticasone furoate (Primary) ; Moxifloxacin
- Indications Asthma; Perennial allergic rhinitis; Rhinosinusitis; Seasonal allergic rhinitis
- Focus Pharmacodynamics
- Sponsors GlaxoSmithKline; GSK
- 14 Jan 2015 New trial record